Compare AstraZeneca plc (AZN) vs T-Rex 2X Inverse MSTR Daily Target ETF (MSTZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs T-Rex 2X Inverse MSTR Daily Target ETF — how do they compare? AstraZeneca plc trades at $158.4 (market cap $248.14B), while T-Rex 2X Inverse MSTR Daily Target ETF trades at $11.35. The key difference: AstraZeneca plc pays a 2.01% dividend while T-Rex 2X Inverse MSTR Daily Target ETF pays none, and T-Rex 2X Inverse MSTR Daily Target ETF is trading nearer its 52-week high, AstraZeneca plc nearer its low. Which is the better fit depends on your goals.
| AZN | MSTZ | |
|---|---|---|
Market Cap | $248.14B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $209.48 | $27.92 |
52-Week Low | $147.06 | $3.88 |
Enterprise Value | $275.41B | — |
Dividend Yield | 2.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.
Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.
MSTZ stock trades at $11.40, showing a 5.36% daily gain amid bearish technical signals. The stock faces selling pressure with moving averages indicating a downtrend, while oscillators remain neutral. Financial ratios including P/E, P/S, and P/B are unavailable in current data. Recent ETF performance news indirectly references momentum names but lacks direct MSTZ coverage.
The outlook remains cautious with technical indicators favoring bearish momentum. Investment opportunity hinges on fundamental improvements currently obscured by missing financial data. Key risks include continued technical weakness and lack of clear fundamental catalysts. Investors should await earnings clarity for directional conviction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About T-Rex 2X Inverse MSTR Daily Target ETF
MSTZ is a leveraged ETF that seeks daily investment results corresponding to 200% of the inverse (opposite) of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bearish position on MSTR, a company known for its large Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from its stated daily objective.
Read more on MSTZ →
